Healthcare
Live Price
Offline$2.63
+1.94% today
1Y Change
-89.60%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tvardi Therapeutics, Inc. (TVRD) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $2.63 and down 89.6% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +94.7%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +94.7%, free cash flow +62.1% with operating margin -964.6% and ROIC -117.2%. Valuation already assumes a fairly strong business story at price/sales 11.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TVRD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TVRD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TVRD Max Drawdown
-93.86%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TVRD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$23.0M
-45.0% YoY
FY Net Income
-$88.4M
-3.5% YoY
Free Cash Flow
-$60.1M
-235.6% YoY
Revenue Growth
-100.0%
EPS Growth
+94.7%
Gross Margin
98.2%
Net Margin
-527.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 7M | 21M | 42M | 23M |
| Gross Profit | 0 | 6M | 15M | 34M | 21M |
| Operating Income | -27M | -56M | -121M | -88M | -89M |
| EBITDA | -27M | -63M | -118M | -84M | -87M |
| Net Income | -18M | -71M | -119M | -85M | -88M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21M | 38M | 23M | 21M | 13M |
| Total Assets | 32M | 44M | 27M | 45M | 247M |
| Total Liabilities | 11M | 48M | 89M | 90M | 20M |
| Shareholder Equity | 21M | -5M | -62M | -45M | 228M |
| Total Debt | 201K | 44M | 368K | 2M | 4M |
| Net Debt | -21M | 7M | -23M | -19M | -10M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
60M
-236.3% YoY
Capital Expenditures
39K
+22.0% YoY
Free Cash Flow
60M
-235.6% YoY
Key ratios
Gross Margin
98.2%
Operating Margin
-964.6%
Net Margin
-527.1%
ROE
-81.3%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.